X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Viracta's lead program, VRx-3996 evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of relapsed or refractory EBV+ peripheral T-cell lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of EBV-related nasopharyngeal carcinoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Nana-val (nanatinostat + valganciclovir) is a combination medicine. Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor. It is being evaluated in phase 1/2 clinical trials for the treatment of Epstein-Barr Virus-positive solid tumors.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoform. It is currently being investigated in combination with valganciclovir for R/R EBV+ PTCL.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-Val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Nana-val (nanatinostat and valganciclovir) is an orally available histone deacetylase inhibitor. It is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoforms, which induces viral genes that are epigenetically silenced in EBV associated malignancies. It is currently being investigated in combination with valganciclovir.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
VRx-3996 (nanatinostat), an orally available HDAC inhibitor, is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies.
Lead Product(s): Nanatinostat,Pembrolizumab,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Nana-val (nanatinostat) is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: Nana-val
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Nana-val (Nanatinostat and Valganciclovir), is an orally available HDAC inhibitor, is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.
Lead Product(s): Nanatinostat,Pembrolizumab,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
